4
4D Molecular Therapeutics, Inc. (FDMT)
NMS – Real Time Price. Currency in USD
10.34
-0.45 (-4.17%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
10.34
-0.45 (-4.17%)
At close: May 12, 2026, 4:00 PM EDT
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
| Name | Position |
|---|---|
| Dr. An Song Ph.D. | Chief Translational Medicine Advisor |
| Dr. David H. Kirn M.D. | Co-Founder, President, CEO & Director |
| Dr. Fariborz Kamal Ph.D. | Chief Technical Advisor |
| Dr. John F. Milligan Ph.D. | Executive Chairman |
| Dr. Katy Barglow Ph.D. | Chief Technical Officer |
| Dr. Noriyuki Kasahara M.D., Ph.D. | Chief Scientific Advisor & Member of Scientific Advisory Board |
| Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal Officer & Corporate Secretary |
| Julian Pei | Head of Investor Relations & Corporate Finance |
| Mr. Kristian Humer M.B.A. | CFO and Principal Financial & Accounting Officer |
| Ms. Theresa Janke | Co-Founder & Chief of Staff |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | fdmt-20260507.htm |
| 2026-05-07 | 10-Q | fdmt-20260331.htm |
| 2026-04-28 | DEFA14A | ny20063669x2_defa14a.htm |
| 2026-04-28 | DEF 14A | ny20063669x1_def14a.htm |
| 2026-03-30 | 8-K | fdmt-20260325.htm |
| 2026-03-18 | 8-K | fdmt-20260318.htm |
| 2026-01-26 | 8-K | fdmt-20260122.htm |
| 2026-01-07 | 8-K | fdmt-20251231.htm |
| 2025-12-10 | 8-K | fdmt-20251210.htm |
| 2025-11-17 | 8-K | d14139d8k.htm |